Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Trial Profile

A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2019

At a glance

  • Drugs Rosiptor (Primary)
  • Indications Pelvic pain; Prostatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Aquinox Pharmaceuticals
  • Most Recent Events

    • 27 Jun 2018 Status changed from recruiting to discontinued, as reported in an Aquinox Pharmaceuticals media release
    • 11 Jun 2018 According to an Aquinox Pharmaceuticals media release, dosing has been initiated.
    • 11 Jun 2018 Status changed from not yet recruiting to recruiting, according to an Aquinox Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top